On December16th, 3rd Annual Bio Cross-border Investment & Partnership Summit: Summary and Outlook was successfully held virtually by MSQ Ventures and The BayHelix Group. This summit consisted of 2 panel discussions, 1 expert speech, and 12 company presentations. The two panel discussions were “How does China joining the ICH Impact the Dynamics of Global Clinical Trial Design? ”, and “A Leap from Regional to Global Deals: China Biopharma’s Licensing Strategy Revolution”. The one expert speech was about “Biotech Hong Kong IPO: Common Legal Issues”.

PANEL DISCUSSION I: “HOW DOES CHINA JOINING THE ICH IMPACT THE DYNAMICS OF GLOBAL CLINICAL TRIAL DESIGN?”

MODERATOR: Alvin Luk, Neurophth, CEO

PANELISTS:

• Roger Luo, Overland Pharmaceuticals, CDO
• Whitney Page, G1 Therapeutics, Head of Alliance Management
• Xin-Yuan Fu, GenEros Biopharma, Chairman & Founder
• Oliver Kong, Qilu Pharmaceutical, CMO

PANEL DISCUSSION II: “A LEAP FROM REGIONAL TO GLOBAL DEALS: CHINA BIOPHARMA’S LICENSING STRATEGY REVOLUTION”

MODERATOR: Dr. Ginger Ding, MSQ Ventures, Managing Director

PANELISTS

• Dr. Eddy Wu, Arctic Vision, CEO
• James Xue, CANbridge Pharmaceuticals, Founder & CEO
• Bing Yuan, Oncusp Therapeutics, Co-Founder & CEO
• Ye Hua, BioNova, CEO

EXPERT SPEECH: “BIOTECH HONG KONG IPO: COMMON LEGAL ISSUES”

Yiming Liu

Yiming represents biotech companies and investment funds on strategic transactions in the life sciences and technology industries. He regularly advises clients on the structuring, negotiation and of a wide range of cross border transactions, including mergers and acquisitions, private equity financings, joint ventures, research collaborations and licensing agreements. Yiming is also widely recognized for his work on life sciences IPOs in Hong Kong and the US. In particular, he is adept in leading the preparation of prospectuses and the discussions and communications with issuers, sponsors, investors and the Hong Kong Exchange as the issuer’s counsel during the listing process.